Relapsed or refractory
Showing 1 - 25 of >10,000
Refractory Cancer, Relapsed Cancer Trial in Weston (Drug Sensitivity Test (DST))
Not yet recruiting
- Refractory Cancer
- Relapsed Cancer
- Drug Sensitivity Test (DST)
-
Weston, FloridaLerner College of Medicine: Cleveland Clinic Florida
Sep 1, 2023
PET-CT Imaging in Relapsed/Refractory Acute Leukemias
Not yet recruiting
- B Cell
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 4, 2023
Relapsed/Refractory Multiple Myeloma Trial in Suzhou (ICI201)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
-
Suzhou, Jiangsu, ChinaFirst Affiliated Hospital, Soochow University
Jul 31, 2023
Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)
Not yet recruiting
- Relapsed/Refractory B-Cell Lymphoma
- FT522
- +4 more
- (no location specified)
Jul 10, 2023
Relapsed/Refractory Multiple Myeloma, Amyloid Light-chain Amyloidosis Trial (SAR445514)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
- Amyloid Light-chain Amyloidosis
- (no location specified)
Apr 20, 2023
Relapsed/Refractory Multiple Myeloma Trial in Benowa (ISB 2001)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
- ISB 2001
-
Benowa, Queensland, AustraliaPindara Private Hospital
May 18, 2023
Relapsed/Refractory B-cell Malignancies Trial (AC676)
Not yet recruiting
- Relapsed/Refractory B-cell Malignancies
- (no location specified)
Mar 27, 2023
SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- +2 more
- (no location specified)
Jun 22, 2023
Relapsed/ Refractory Multiple Myeloma Trial (GC012F)
Not yet recruiting
- Relapsed/ Refractory Multiple Myeloma
- GC012F
- (no location specified)
Apr 28, 2023
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Venetoclax)
Not yet recruiting
- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory
- (no location specified)
Oct 30, 2023
Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome, Relapsed/Refractory Acute Myeloid Leukemia Trial (Magrolimab)
Available
- Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome
- Relapsed/Refractory Acute Myeloid Leukemia
- Magrolimab
- (no location specified)
Jan 18, 2023
Relapsed/Refractory Multiple Myeloma Trial in Suzhou (Mitoxantrone HCl liposome/Dexamethasone/daratumumab)
Recruiting
- Relapsed/Refractory Multiple Myeloma
- Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab
-
Suzhou, Jiangsu, ChinaSecond Affiliated Hospital of Soochow University
May 4, 2023
CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,
Not yet recruiting
- CD19-positive Relapsed or Refractory B-cell Malignancies
- UTAA09 cells for infusion
- +2 more
-
Hefei, Anhui, ChinaThe First Affiliated Hospital of USTC (AnHui Provincial Hospital
Oct 13, 2023
Relapsed/Refractory AML Trial in Suzhou (Selinexor, Homoharringtonine, Cytarabine)
Not yet recruiting
- Relapsed/Refractory AML
- Selinexor
- +6 more
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Mar 28, 2023
Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)
Not yet recruiting
- Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
- (no location specified)
Sep 5, 2023
AML, MDS Trial in Tuebingen (Decitabine, Venetoclax)
Recruiting
- AML
- MDS
-
Tuebingen, Baden-Wuerttemberg, GermanyUniversity Hospital
Nov 30, 2023
Relapsed or Refractory (R/R) Primary CNS Lymphoma Trial in Nanjing (thiotepa combined with pomalidomide)
Recruiting
- Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
- thiotepa combined with pomalidomide
-
Nanjing, Jiangsu, ChinaJiangsu Province People's Hospital.
Jun 27, 2023
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022
Not yet recruiting
- Cancer
- Relapsed/Refractory Large B-cell Lymphoma (LBCL)
- Fludarabine (30 mg/m^2)
- +2 more
- (no location specified)
Jul 25, 2023
Lymphoma, Primary Effusion Trial run by the National Cancer Institute (NCI) (Daratumumab SC)
Not yet recruiting
- Lymphoma, Primary Effusion
- Daratumumab SC
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jun 23, 2023
Relapsed/Refractory Acute Myeloid Leukemia Trial in Hangzhou (B7-H3 target, CAR gene modified gdT cell injection)
Recruiting
- Relapsed/Refractory Acute Myeloid Leukemia
- B7-H3 target, CAR gene modified gdT cell injection
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, Zhejiang University School of Med
Feb 15, 2023
Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Duarte, Amsterdam (BMS-986458, Rituximab)
Not yet recruiting
- Relapsed/Refractory Non-Hodgkin Lymphoma
-
Duarte, California
- +1 more
Oct 13, 2023
Mantle-cell Lymphoma Trial (Polatuzumab, bendamustin und rituximab)
Not yet recruiting
- Mantle-cell Lymphoma
- Polatuzumab, bendamustin und rituximab
- (no location specified)
May 11, 2023
Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in China (AXT-1003)
Not yet recruiting
- Relapsed or Refractory Non-Hodgkin's Lymphoma
-
Beijing, China
- +3 more
Jul 20, 2023
Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in Miami (Iberdomide, Carfilzomib, Daratumumab)
Not yet recruiting
- Refractory Multiple Myeloma
- Relapsed Multiple Myeloma
- Iberdomide
- +6 more
-
Miami, FloridaUniversity of Miami
May 31, 2023